Press Releases

February 22, 2019
Gossamer Bio Announces Participation in Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2019-- Gossamer Bio, Inc.  (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila
Additional Formats
PDF Version
February 7, 2019
Gossamer Bio Announces Pricing of Initial Public Offering
SAN DIEGO --(BUSINESS WIRE)--Feb. 7, 2019-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its
Additional Formats
PDF Version
January 30, 2019
Gossamer Bio Announces Updates Regarding its Initial Public Offering
SAN DIEGO--( BUSINESS WIRE )--Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed an amended registration
Additional Formats
PDF Version
January 23, 2019
Gossamer Bio Announces Commencement of Initial Public Offering
SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed a registration statement on Form
Additional Formats
PDF Version